This text has been reposted from an earlier press release from INOVIQ Limited.
Melbourne, Australia, 8 February 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to announce positive results from an independent retrospective case-control study to evaluate the performance of its SubB2M-CA15.3 breast cancer test across all stages of breast cancer.
Read full story here: ASX Announcement (inoviq.com)